Antimetabolite Treatment for Pancreatic Cancer.

Abstract

Pancreatic cancer is a deadly and aggressive disease. Less than 1% of diagnosed patients survive 5 years with an average survival time of only 4-8 months. The only option for metastatic pancreatic cancer is chemotherapy where only the antimetabolites gemcitabine and 5-fluorouracil are used clinically. Unfortunately, efforts to improve chemotherapy regimens by combining, 5-fluorouracil or gemcitabine with other drugs, such as cisplatin or oxaliplatin, have not increased cell killing or improved patient survival. The novel antimetabolite zebularine shows promise, inducing apoptosis and arresting cellular growth in various pancreatic cancer cell lines. However, resistance to these antimetabolites remains a problem highlighting the need to discover and develop new antimetabolites that will improve a patient's overall survival.

• Authors: Malyn May Asuncion Valenzuela, Jonathan W Neidigh, Nathan R Wall
• Journal: Chemotherapy (Chemotherapy (Los Angel)) Vol. 3 Issue 3 (Dec 2014) ISSN: 2167-7700 [Print] United States
• PMID: 26161298 (Publication Type: Journal Article)